IL1A and Crohn disease: Thus, IL-1α has become an important drug target in many diseases (Dinarello et al., 2012) such as sepsis (Benjamin et al., 2018), chronic toxoplasma infection (Batista et al., 2020), inflammatory bowel disease, Crohn’s disease, and diabetes mellitus (Collier et al., 2021).